Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating VIA Disc NP, a non-surgical treatment designed to supplement the nucleus pulposus tissue in degenerated intervertebral discs. This randomized, sham-controlled, multi-center, double-blind clinical trial includes participants with lumbar discogenic pain related to degenerative disc disease DDD. The study aims to assess the safety and effectiveness of this treatment for managing moderate to severe disc-related back pain. Participants will receive one VIA Disc NP treatment injected into each affected disc level, with up to two levels treated per person. After an initial open-label roll-in period, participants are randomized in a 21 ratio to receive either the VIA Disc NP injection or a sham procedure that mimics the treatment without injecting any material. Participants in the sham group who still have symptoms after 12 months may cross over to receive the VIA Disc NP treatment and continue follow-up for another 12 months. During the study, participants will be closely monitored through scheduled visits to evaluate pain reduction using the Visual Analog Scale VAS and to record any treatment-related adverse events over 12 months. The main outcomes include the proportion of participants achieving meaningful pain improvement and the frequency of adverse events related to the treatment. Follow-up assessments and monitoring will continue throughout the study duration, which extends up to the study completion date in October 2028.
Actively Recruiting
Researchers are conducting a phase 3 multicenter, randomized, triple-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of intravenous neridronate AMBTX-01 in adults diagnosed with the warm subtype of Complex Regional Pain Syndrome Type 1 CRPS-1 confirmed by a positive triple phase bone scan. The study targets participants with symptoms onset within 6 months and aims to compare neridronate with placebo in treating this painful condition. Participants will receive either 400 mg of neridronate or a placebo, administered as a 2-hour intravenous infusion on Days 1, 4, 7, and 10. The trial spans approximately 18 weeks, including a screening period of 2 to 6 weeks, the treatment dosing over 10 days, and a post-treatment follow-up period lasting through Week 12 to monitor effects and safety. During the study, participants will undergo various assessments including pain intensity measurements, CRPS severity scoring, health surveys, range of motion tests, and monitoring of rescue medication use at multiple timepoints from Day 10 up to Week 12. Data collection includes patient and clinician global impressions, sleep interference scales, and physical function evaluations. Researchers will also track safety and tolerability throughout the trial.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.